Aqueous extracts of Fructus Ligustri Lucidi enhance the sensitivity of human colorectal carcinoma DLD-1 cells to doxorubicin-induced apoptosis via Tbx3 suppression

Integrative Cancer Therapies

Volumn 10, Issue 1, 2011, Pages 85-91

  Zhang, Jin Fang ^a,b   He, Ming Liang ^b   Dong, Qi ^b   Xie, Wei Dong ^a   Chen, Yang Chao ^b   Lin, Marie C M ^c   Leung, Ping Chung ^b   Zhang, Ya Ou ^a   Kung, Hsiang Fu ^a,b  

^a TSINGHUA UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

apoptosis; doxorubicin; Fructus Ligustri Lucidi; sensitivity

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOXORUBICIN; LIGUSTRUM LUCIDUM EXTRACT; PROTEIN P14; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TBX3; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL PROLIFERATION; COLORECTAL CARCINOMA; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DOXORUBICIN; DRUG SYNERGISM; HUMANS; LIGUSTRUM; PLANT EXTRACTS; RNA, SMALL INTERFERING; T-BOX DOMAIN PROTEINS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79953728787     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735410373921     Document Type: Article

References (21)

1. Benson AB. Epidemiology, disease progression, and economic burden of colorectal cancer. J Manag Care Pharm. 2007;13:S5-S18.
2. Hawk ET, Levin B. Colorectal cancer prevention. J Clin Oncol. 2005;23:378-391. (Pubitemid 46206885)
3. Committee of National Pharmacopoeia. Pharmacopoeia of P. R. China. Beijing, China: Committee of National Pharmacopoeia; 2005:34.
4. Chen G, Zhang LY, Wu XL, Ye JN. Determination of mannitol and three sugars in Ligustrum lucidum Ait by capillary electrophoresis with electrochemical detection. Analytica. 2005;530:15-31.
5. Manu KA, Kuttan G. Ursolic acid induces apoptosis by activating p53 and caspase-3 gene expressions and suppressing NF-kappaB mediated activation of bcl-2 in B16F-10 melanoma cells. Int Immunopharmacol. 2008;8:974-981.
6. Yamai H, Sawada N, Yoshida T, et al. Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo. Int J Cancer. 2009;125:952-960.
7. Bonaccorsi I, Altieri F, Sciamanna I, et al. Endogenous reverse transcriptase as a mediator of ursolic acid's anti-proliferative and differentiating effects in human cancer cell lines. Cancer Lett. 2008;263:130-139.
8. Li G, Chan CY, Zhang JF, et al. the aqueous extract of Fructus Ligustri Lucidi regulates the differentiation of human mesenchymal stem cell. Int J Integr Biol. 2008;3:182-190.
9. Zhang Y, Lai WP, Leung PC, Che CT, Wong MS. Improvement of Ca balance by Fructus Ligustri Lucidi extract in aged female rats. Osteoporos Int. 2008;19:235-242.
10. Carlson H, Ota S, Song Y, et al. Tbx3 impinges on the P53 pathway to suppress apoptosis, facilitate cell transformation and block myogenic differentiation. Oncogene. 2002;21: 3827-3835.
11. ARF) and is amplified in a subset of human breast cancers. Nat Genet. 2000;26:291-299.
12. Temple HT. Clinical evaluation and treatment of soft tissue tumors. Semin Musculoskelet Radiol. 1999;3:5-14. (Pubitemid 29318996)
13. Lowe S, Ruley H, Jacks T, Housman D. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957-967. (Pubitemid 23289454)
14. Lowe S, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266:807-810. (Pubitemid 24359290)
15. Blagosklonny M, El-Deiry W. Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. Int J Cancer. 1998;75:933-940. (Pubitemid 28134120)
16. Renard C, Labalette C, Armengol C, et al. Tbx3 is a downstream target of the wnt-B catenin pathway and a critical mediator of B-catenin survival functions in liver cancer. Cancer Res. 2007;67:901-910.
17. Bamshad M, Lin RC, Law DJ, et al. Mutation in human TBX3 alter limb, apocrine and gential development in ulnar-mammary syndrome. Nat Genet. 1997; 16:311-315. (Pubitemid 27280219)
18. Brummelkamp TR, Kortlever RM, Lingbeek M, et al. TBX-3, the gene mutated in ulnar-mammary syndrome, is a negative regulator of p19ARF and inhibits senescence. J Biol Chem. 2002;277:6567-6572. (Pubitemid 34968456)
19. Humbey O, Pimkina J, Zilfou JT, et al. The ARF tumor suppressor can promote the progression of some tumors. Cancer Res. 2008;68:9608-9613.
20. Lingbeek ME, Jacobs JJ, van Lohuizen M. The T-box repressors TBX2 and TBX3 specifically regulate the tumor suppressor gene p14ARF via a variant T-site in the initiator. J Biol Chem. 2002;277:26120-26127. (Pubitemid 34967096)
21. Yarosh W, Barrientos T, Esmailpour T, et al. TBX3 is overexpressed in breast cancer and represses p14 ARF by interacting with histone deacetylases. Cancer Res. 2008;68:693-699. (Pubitemid 351206744)